2.41

0.00% 0.00

After Hours: 2.41

Lisata Therapeutics Inc (LSTA)

Overview News Price History Financials Discussions Forecast Stock Split

Lisata Therapeutics Inc stock is traded at $2.41, with a volume of 6,096. It is up +0.00% in the last 24 hours and up +21.11% over the past month. Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Previous Close:

$2.41

Open:

$2.37

24h Volume:

6,096

Relative Volume:

0.41

Market Cap:

$21.81M

Revenue:

Net Income/Loss:

$-20.74M

P/E Ratio:

-0.9602

EPS:

-2.51

Net Cash Flow:

$-18.90M

1W Performance:

-4.74%

1M Performance:

+21.11%

6M Performance:

-16.32%

1Y Performance:

-15.44%

1-Day Range:

$2.36

$2.50

1-Week Range:

$2.30

$2.55

52-Week Range:

$1.87

$4.20

Lisata Therapeutics Inc Stock (LSTA) Company Profile

Name

Lisata Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (676)

Phone

908-229-2590

Address

110 ALLEN ROAD, BASKING RIDGE

Employee

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

LSTA's Discussions on Twitter

Compare LSTA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LSTA Lisata Therapeutics Inc	2.41	21.81M	0	-20.74M	-18.90M	-2.51
VRTX Vertex Pharmaceuticals Inc	500.19	127.64B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	603.58	65.95B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	656.65	37.92B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	273.55	32.98B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	254.16	26.92B	3.81B	-644.79M	-669.77M	-6.24

Lisata Therapeutics Inc Stock (LSTA) Latest News

May 01, 2025

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025 - The Manila Times

May 01, 2025

Lisata Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire

May 01, 2025

Lisata Therapeutics Earnings: Solid Tumor Treatment Developer Reports Q1 2025 Results May 8 - Stock Titan

May 01, 2025

Apr 26, 2025

Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI - Proactive financial news

Apr 20, 2025

Apr 17, 2025

Lisata Therapeutics announces research license with Catalent - MSN

Apr 17, 2025

Apr 16, 2025

Lisata Therapeutics CMO discusses potential for certepetide under Catalant license agreement - Proactive financial news

Apr 16, 2025

Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement - Proactive Investors

Apr 16, 2025

Apr 15, 2025

Market movers: Meta, HPE, Applied Digital, Lisata Therapeutics... - Proactive Investors

Apr 15, 2025

Lisata Therapeutics (LSTA) Partners with Catalent on Preclinical Study | LSTA Stock News - GuruFocus

Apr 15, 2025

Lisata Therapeutics Announces Research License with Catalent - GlobeNewswire

Apr 15, 2025

Lisata Therapeutics, Inc. Announces Research License with Catalent, Inc - marketscreener.com

Apr 15, 2025

Lisata falls after mid-stage data for anticancer agent - MSN

Apr 15, 2025

Apr 12, 2025

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’ - MarketScreener

Apr 12, 2025

Apr 05, 2025

Neostem stock plunges to 52-week low at $2.01 amid market challenges - Investing.com Australia

Apr 05, 2025

Apr 04, 2025

Neostem stock plunges to 52-week low at $2.01 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Mar 21, 2025

Healthcare investment strategies reshaped by inflation, interest rates and M&A in 2025 - Proactive financial news

Mar 21, 2025

Mar 18, 2025

Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR.com

Mar 18, 2025

Mar 08, 2025

Lisata Therapeutics CEO discusses AI drug discovery collaborationICYMI - Proactive Investors

Mar 08, 2025

Mar 07, 2025

Lisata Therapeutics expands drug discovery with GATC AI collaboration - Proactive Investors USA

Mar 07, 2025

Lisata Therapeutics expands drug discovery with GATC AI collaboration | NASDAQ:LSTA - Proactive Investors

Mar 07, 2025

Mar 06, 2025

Lisata Therapeutics to Present at the Investival Showcase USA - The Manila Times

Mar 06, 2025

Can This Clinical-Stage Pharma Company Transform Solid Tumor Treatment? CEO Presents Next Month - StockTitan

Mar 06, 2025

Mar 05, 2025

Lisata Therapeutics and GATC Health Consummate First Step - GlobeNewswire

Mar 05, 2025

Market movers: General Motors, Moderna, CrowdStrike, Lisata... - Proactive Investors UK

Mar 05, 2025

Lisata Therapeutics And GATC Health Partner To Accelerate Drug Development Using AI Technology - Nasdaq

Mar 05, 2025

Lisata Therapeutics partners with GATC Health to advance AI-driven drug development - Proactive Investors UK

Mar 05, 2025

Can AI Revolutionize Lisata's Pancreatic Cancer Drug? New GATC Health Partnership Aims to Prove It - StockTitan

Mar 05, 2025

Neostem stock hits 52-week low at $2.15 amid market challenges - Investing.com Australia

Mar 05, 2025

Mar 03, 2025

Neostem stock hits 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa

Mar 03, 2025

Feb 28, 2025

Lisata Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks

Feb 28, 2025